

Cover Story
A demonstration project in which the Centers for Medicare& Medicaid Services hopes to investigate the impact of reimbursement based on Average Sales Prices of drugs is running into strong opposition, as a large number of cancer groups submitted public comments urging the agency to abandon the endeavor.
In Brief


Drugs & Targets
Trending Stories
- Cancer hospitals brace for impact, as CMS moves to slash 340B payments by 33%
- Maura Gillison, who identified the role of HPV in head and neck cancer, changing the standard of care, dies at 61
- The Susan Wojcicki Foundation pushes for rethinking of strategies for early lung cancer detection
- Vermont researchers discover transmissible cancer in catfish—first ever in a freshwater animal
- Mail-out colorectal cancer screening programs extend, rather than replace, clinical care
- Patricio Polanco named chief of surgical oncology and surgeon-in-chief at Atrium Health Levine Cancer











